Страна: Канада
мова: англійська
Джерело: Health Canada
MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y; TETANUS TOXOID
PFIZER CANADA ULC
J07AH04
MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN
5MCG; 5MCG; 5MCG; 5MCG; 44MCG
KIT
MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 5MCG; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 5MCG; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 5MCG; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 5MCG; TETANUS TOXOID 44MCG
INTRAMUSCULAR
0.5ML/10X0.5ML
Schedule D
VACCINES
Active ingredient group (AIG) number: 0554131001; AHFS:
APPROVED
2013-03-05
_ _ _NIMENRIX (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Product Monograph _ _Page 1 of 43_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION NIMENRIX® Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine Powder and diluent for solution for injection Active Immunizing Agent ATC Code J07AH08 Pfizer Canada ULC 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 ® GlaxoSmithKline Biologicals SA Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2023 Date of Initial Authorization: March 5, 2013 Date of Revision: November 28, 2023 Submission Control Number: 273117 _ _ _NIMENRIX (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Product Monograph_ _ _ _Page 2 of 43_ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION 05/2022 7 WARNINGS AND PRECAUTIONS 05/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics .............................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations .............................................................................. Прочитайте повний документ